Showing 3831-3840 of 4165 results for "".
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas
- Study: Early Anti-VEGF Treatment of Diabetic Retinopathy Slows Progression but Yields No Benefit to Visual Acuityhttps://modernod.com/news/study-early-anti-vegf-treatment-of-diabetic-retinopathy-slows-progression-but-yields-no-benefit-to-visual-acuity/2481399/While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network. The study was funded by the National Eye Institute
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- FDA Clears IND Application for Huidagene Therapeutics' RPE65 Mutation-Associated Inherited Retinal Dystrophieshttps://modernod.com/news/fda-clears-ind-application-for-huidagene-therapeutics-rpe65-mutation-associated-inherited-retinal-dystrophies/2481373/HuidaGene Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for the planned multi-national clinical trial of HG004 for the treatment of patients suffering from RPE65 mutation-associated inherited retinal dystrophies.
- Horizon Therapeutics Announces Phase 2 Trial Results Evaluating Dazodalibep for the Treatment of Sjögren’s Syndromehttps://modernod.com/news/horizon-therapeutics-announces-phase-2-trial-results-evaluating-dazodalibep-for-the-treatment-of-sjogrens-syndrome/2481357/Horizon Therapeutics announced that the primary endpoint was met for the second population in its phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome. The phase 2 trial evaluated two patient populations and positive results in the first patient po
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerabilityhttps://modernod.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/Glaukos announced positive results for a prospective, multicenter clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the phase
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Thea Pharma Announces FDA Approval of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-fda-approval-of-glaucoma-drug-iyuzeh/2481294/Thea Pharma announced FDA approval of Iyuzeh (latanoprost ophthalmic solution) 0.005% for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Iyuzeh is the first and only clinically proven formulation of latanoprost available in the Unite
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a